Synthesis and evaluation of coumarin derivatives on antioxidative, tyrosinase inhibitory activities, melanogenesis, and in silico investigations
New coumarin derivatives were designed using a 2-(2-oxo-2 H -chromen-4-yl)acetic acid scaffold conjugated with amino acid esters or tyramine. The anti-tyrosinase and anti-lipid peroxidation activities of the synthesized compounds were investigated. Coumarin derivatives 7 , 9 , 11 – 13 , 15 – 18 show...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2024-03, Vol.14 (1), p.5535-5535, Article 5535 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | New coumarin derivatives were designed using a 2-(2-oxo-2
H
-chromen-4-yl)acetic acid scaffold conjugated with amino acid esters or tyramine. The anti-tyrosinase and anti-lipid peroxidation activities of the synthesized compounds were investigated. Coumarin derivatives
7
,
9
,
11
–
13
,
15
–
18
showed strong anti-lipid peroxidation activity. Compound
13
exhibited uncompetitive tyrosinase inhibitory activity with an IC
50
value of 68.86 µM. Compound
14
(% activity = 123.41) showed stronger tyrosinase activating activity than 8-methoxypsolaren (8-MOP, % activity = 109.46). In silico studies revealed different poses between the inhibitors and activators near the tyrosinase catalytic site. Compounds
13
(25–50 μM) and
14
(25–100 μM) did not show cytotoxicity against B16F10 cells. In contrast to the tyrosinase inhibition assay, compound
13
(50 μM) suppressed melanogenesis in B16F10 cells with two times higher potency than KA (100 μM). Compound
14
at 100 μM showed melanogenesis enhancement in B16F10 cells in a dose-dependent manner, however, inferior to the 8-MOP. Based on the findings, compound
13
and
14
offer potential for development as skin-lightening agents and vitiligo therapy agents, respectively. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-024-54665-x |